公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2022 | Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial | Kelley, Robin Kate; Rimassa, Lorenza; ANN-LII CHENG ; Kaseb, Ahmed; Qin, Shukui; Zhu, Andrew X; Chan, Stephen L; Melkadze, Tamar; Sukeepaisarnjaroen, Wattana; Breder, Valery; Verset, Gontran; Gane, Edward; Borbath, Ivan; Rangel, Jose David Gomez; Ryoo, Baek-Yeol; Makharadze, Tamta; Merle, Philippe; Benzaghou, Fawzi; Banerjee, Kamalika; Hazra, Saswati; Fawcett, Jonathan; Yau, Thomas | The Lancet. Oncology | 210 | 185 | |
2024 | Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study | Yau, Thomas; Kaseb, Ahmed; ANN-LII CHENG ; Qin, Shukui; Zhu, Andrew X; Chan, Stephen L; Melkadze, Tamar; Sukeepaisarnjaroen, Wattana; Breder, Valery; Verset, Gontran; Gane, Edward; Borbath, Ivan; Rangel, Jose David Gomez; Ryoo, Baek-Yeol; Makharadze, Tamta; Merle, Philippe; Benzaghou, Fawzi; Milwee, Steven; Wang, Zhong; Curran, Dominic; Kelley, Robin Kate; Rimassa, Lorenza | The lancet. Gastroenterology & hepatology | 3 | | |
2023 | Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study | Qin, Shukui; Chan, Stephen L; Gu, Shanzhi; Bai, Yuxian; Ren, Zhenggang; Lin, Xiaoyan; Chen, Zhendong; Jia, Weidong; Jin, Yongdong; Guo, Yabing; Hu, Xiaohua; Meng, Zhiqiang; Liang, Jun; Cheng, Ying; Xiong, Jianping; Ren, Hong; Yang, Fang; Li, Wei; Chen, Yajin; Zeng, Yong; Sultanbaev, Alexander; Pazgan-Simon, Monika; Pisetska, Margaryta; Melisi, Davide; Ponomarenko, Dmitriy; Osypchuk, Yurii; Sinielnikov, Ivan; Yang, Tsai-Sheng; Liang, Xiao; Chen, Chunxia; Wang, Linna; ANN-LII CHENG ; Kaseb, Ahmed; Vogel, Arndt; CHIUN HSU | Lancet (London, England) | 71 | 16 | |
2013 | Cancerous Inhibitor of Protein Phosphatase 2A Mediates Bortezomib-Induced Autophagy in Hepatocellular Carcinoma Independent of Proteasome | Yu H.-C.; Hou D.-R.; Liu C.-Y.; Lin C.-S.; Shiau C.-W.; ANN-LII CHENG ; Chen K.-F. | PLoS ONE | 41 | 93 | |
2008 | Carbonic anhydrase III promotes transformation and invasion capability in hepatoma cells through FAK signaling pathway | Dai H.-Y.; Hong C.-C.; Liang S.-C.; Yan M.-D.; Lai G.-M.; ANN-LII CHENG ; Chuang S.-E. | Molecular Carcinogenesis | 38 | 35 | |
2020 | A case-control study of perfluoroalkyl substances and the risk of breast cancer in Taiwanese women | Lien, Guang-Wen; WU-SHIUN HSIEH ; WEN-HUNG KUO ; CHING-HUA KUO ; Huang, Ching-Chun; YUE-LIANG GUO; DWANG-YING CHANG ; YEN-SHEN LU ; CHIUN-SHENG HUANG ; ANN-LII CHENG ; CHING-HUNG LIN ; PAU-CHUNG CHEN | Environment International | 49 | 35 | |
2015 | Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations | YI-HSIN LIANG ; Lin Y.-L.; JAU-YU LIAU ; JIA-HUEI TSAI ; JIN-TUNG LIANG ; BEEN-REN LIN ; JI-SHIANG HUNG ; LI-HUI TSENG ; LIANG-IN LIN ; YIH-LEONG CHANG ; ANN-LII CHENG ; KUN-HUEI YEH | Anticancer Research | 4 | 4 | |
2020 | Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma | ANN-LII CHENG ; CHIUN HSU ; Chan S.L.; Choo S.-P.; Kudo M. | Journal of Hepatology | 297 | 267 | |
2011 | Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib | Faivre S.; Zappa M.; Vilgrain V.; Boucher E.; Douillard J.-Y.; Lim H.Y.; Kim J.S.; Im S.-A.; Kang Y.-K.; Bouattour M.; Dokmak S.; Dreyer C.; Sablin M.-P.; Serrate C.; ANN-LII CHENG ; Lanzalone S.; Lin X.; Lechuga M.J.; Raymond E. | Clinical Cancer Research | 72 | 67 | |
2020 | A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements | Kudo M.; Han K.-H.; Ye S.-L.; Zhou J.; Huang Y.-H.; Lin S.-M.; Wang C.-K.; Ikeda M.; Chan S.L.; Choo S.P.; Miyayama S.; ANN-LII CHENG | Liver Cancer | 150 | 146 | |
1994 | Characteristic clinicopathologic features of adult B‐cell lymphoblastic lymphoma with special emphasis on differential diagnosis with an atypical form probably of blastic lymphocytic lymphoma of intermediate differentiation origin | ANN-LII CHENG ; Su I.‐J.; HWEI-FANG TIEN ; Wang C.‐C.; YAO-CHANG CHEN ; Wang C.‐H. | Cancer | 18 | | |
1993 | Characteristic clinicopathologic features of epstein-barr virus—associated peripheral T-cell lymphoma | ANN-LII CHENG ; Ih-Jen Su; YAO-CHANG CHEN ; Wu-Ching Uen; Chiu-Hwa Wang | Cancer | 82 | | |
2010 | Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions | YU-YUN SHAO ; Hu F.-C.; JIN-TUNG LIANG ; Chiu W.-T.; ANN-LII CHENG ; CHIH-HSIN YANG | Journal of the Formosan Medical Association | 27 | 23 | |
1988 | Characterization of the spectrum of postthymic T‐cell malignancies in Taiwan a clinicopathologic study of HTLV‐1‐positive and HTLV‐1‐negative cases | Su I.-J.; Wang C.-H.; ANN-LII CHENG ; YAO-CHANG CHEN ; Hsieh H.-C.; HWEI-FANG TIEN ; Huang S.-S.; CHUNG-YI HU ; PEI-JER CHEN ; Chen J.-Y.; Hsu H.-C.; Chuang S.-M.; MING-CHING SHEN ; Kadin M.E. | Cancer | 45 | | |
2002 | The chemopreventive compound curcumin is an efficient inhibitor of Epstein-Barr virus BZLF1 transcription in Raji DR-LUC cells | Hergenhahn M.; Soto U.; Weninger A.; Polack A.; CHIH-HUNG HSU ; ANN-LII CHENG ; Rösl F. | Molecular Carcinogenesis | 70 | 61 | |
2017 | Chemotherapy alone is an alternative treatment in treating localized primary ocular adnexal lymphomas | WEI-LI MA ; MING YAO ; SHU-LANG LIAO ; JIH-LUH TANG ; Wang Y.-C.; SUNG-HSIN KUO ; ANN-LII CHENG | Oncotarget | 6 | 4 | |
2000 | Chemotherapy alone versus, surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach | Liu H.-T.; CHIUN HSU ; Chen C.-L.; Chiang I.-P.; Chen L.-T.; YAO-CHANG CHEN ; ANN-LII CHENG | American Journal of Hematology | 34 | | |
2014 | Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study | CHIUN HSU ; Tsou H.-H.; Lin S.-J.; Wang M.-C.; MING YAO ; Hwang W.-L.; Kao W.-Y.; Chiu C.-F.; Lin S.-F.; Lin J.; Chang C.-S.; HWEI-FANG TIEN ; Liu T.-W.; PEI-JER CHEN ; ANN-LII CHENG | Hepatology | 227 | 210 | |
2014 | Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers | HSIANG-FONG KAO ; I-CHUN CHEN ; CHIUN HSU ; Chang S.-Y.; Chien S.-F.; YEE-CHUN CHEN ; Hu F.-C.; CHIH-HSIN YANG ; ANN-LII CHENG ; KUN-HUEI YEH | Supportive Care in Cancer | 10 | 10 | |
1996 | Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma | ANN-LII CHENG ; YAO-CHANG CHEN ; KUN-HUEI YEH ; Chuang S.-E.; Chen B.-R.; DING-SHINN CHEN | Cancer | 37 | | |